Thursday, November 25, 2010
Wednesday, November 24, 2010
Monday, November 8, 2010
HOW TO BE SUCCESSFUL IN THE BUSINESS OF PHOTOGRAPHY 2
src='http://bhphoto.pb.feedroom.com/bhphoto/bhphoto/pboneclipab/player.swf?Environment=&SiteID=bhphoto&SiteName=bhphoto&SkinName=pboneclipab&ChannelID=&StoryID=75743751e7268e6cf515ed5fb32ddecab8b55d86&Volume=.5&MoreVideoURL=http%3A//www.video.bhphotovideo.com&tilenumber=&VideoPlayer.VideoPlayer1.SendEMailURL=http%3A//%25SiteID%25.feedroom.com/custom/playerbuilder/feedroom/sendMail.jsp&VideoPlayer.VideoPlayer1.MaximumNumberOfStories=&tilemargin=&videoratio=&detailsheight='
Wednesday, October 13, 2010
Saturday, August 21, 2010
Friday, August 20, 2010
.jpg)
Monday, August 16, 2010
Dr Chow Yok Wai- CME for general practitioners. 1)Treating Diabetes Mellitus in 2010 The Role of DPP4 inhibitors 2) Hypertension in clinical practice
Speaker:
Dr Chow Yok Wai
MD, MRCP(UK), AM(Mal)
Consultant Nephrologist and Physician
Hospital Pantai Ayer Keroh, Melaka
Topic:
1. Treating Diabetes Mellitus in 2010. The Role of DPP4 inhibitors
2. Hypertension in clinical practice
Venue:
Classic Hotel
Time:
7.00pm
Who should attend:
General practitioners
Medical officers
Dr Chow Yok Wai
MD, MRCP(UK), AM(Mal)
Consultant Nephrologist and Physician
Hospital Pantai Ayer Keroh, Melaka
Topic:
1. Treating Diabetes Mellitus in 2010. The Role of DPP4 inhibitors
2. Hypertension in clinical practice
Venue:
Classic Hotel
Time:
7.00pm
Who should attend:
General practitioners
Medical officers
Sunday, August 1, 2010
Kluang CME - 1) Diabetic Nephropathy by Dr CHow Yok Wai 2) Advances in Prostate Surgery by Dr Pang Kim Keng
CME Talks in Kluang
1. Diabetic Nephropathy- What's new
Dr Chow Yok Wai,
Consultant Nephrologist and Physician,
Hospital Pantai Ayer Keroh, Melaka
2. Modern management of Prostate Diseases
Dr Pang Kim Keng
Consultant Urologist,
Hospital Pantai Ayer Keroh, Melaka
Date: 26th August 2010
Time: 5.00pm
Venue: To be announced
Target audience: Doctors
1. Diabetic Nephropathy- What's new
Dr Chow Yok Wai,
Consultant Nephrologist and Physician,
Hospital Pantai Ayer Keroh, Melaka
2. Modern management of Prostate Diseases
Dr Pang Kim Keng
Consultant Urologist,
Hospital Pantai Ayer Keroh, Melaka
Date: 26th August 2010
Time: 5.00pm
Venue: To be announced
Target audience: Doctors
Friday, July 16, 2010
Hypertension- Translating guidelines into Clinical Practice- Dr Chow Yok Wai
Topic : Hypertension- Translating guidelines into Clinical Practice
Speaker: Dr Chow Yok Wai, Consultant Nephrologist and Physician,
Hospital Pantai Ayer Keroh, Melaka
Date: 16/7/2010 7.00pm
Venue: Ramada Renaissance Melaka
Who should attend?
General Practitioners/Primary care physicians
Physicians/Registrar/Medical Officers
Sunday, June 6, 2010
Public Forum- Yong Peng by Dr Chow Yok Wai and Dr Pang Kim Keng
Date : 26/6/2010 (Saturday)
Venue : Yong Peng High School
(Jalan Sekolah Cina, 83700 Yong Peng, Johor)
Time : 6.30pm - 10.00pm
Target of Pax : 150 pax
Speakers: Dr Pang Kim Keng, Consultant Urologist, Hospital Pantai Ayer Keroh, Melaka
Dr Chow Yok Wai, Consultant Nephrologist, Hospital Pantai Ayer Keroh, Melaka
Programme : 6.30pm - Registration
7.00pm - Talk by Dr Pang and Q&A (Common Urological Diseases)
8.00pm - Talk by Dr Chow and Q&A (Protect you kidneys, Control diabetes)
9.00pm - Blood Pressure and Blood Glucose Screening
Venue : Yong Peng High School
(Jalan Sekolah Cina, 83700 Yong Peng, Johor)
Time : 6.30pm - 10.00pm
Target of Pax : 150 pax
Speakers: Dr Pang Kim Keng, Consultant Urologist, Hospital Pantai Ayer Keroh, Melaka
Dr Chow Yok Wai, Consultant Nephrologist, Hospital Pantai Ayer Keroh, Melaka
Programme : 6.30pm - Registration
7.00pm - Talk by Dr Pang and Q&A (Common Urological Diseases)
8.00pm - Talk by Dr Chow and Q&A (Protect you kidneys, Control diabetes)
9.00pm - Blood Pressure and Blood Glucose Screening
Monday, March 15, 2010
Monday, March 8, 2010
Tuesday, February 9, 2010
How to sell yourself
To get ahead in life, you need to be in the business of selling.
The product? You !
When you think about it, if you cannot sell yourself as a person to others, you are going to have a difficult time selling them your ideas, your wishes, your needs, your ambitions, your skills, and your experience.
Despite the necessity of being able to sell yourself to others, for many people like myself it does not come naturally. Introversion, shyness, and lack of self-worth are just a few of the obstacles that can potentially get in the way. To overcome such obstacles, I suggest focusing on the following:
1. Be Sold on Yourself
This is probably also the hardest. Being sold on yourself comes down to this: you must be aware of your own self-worth. This means you believe in yourself, have faith in yourself, and have confidence in yourself.
Here are just 3 ideas that may help:
* Live in such a way that you would want to be friends with yourself
* Find some time to reflect on what you like about yourself. If this seems hard, start with the smallest of attributes.
* Don’t do anything that will give you cause to feel ashamed later.
2. Have a Saleable Package
Let others know about the inner contents of your package.
People judge others based on their appearance.
Therefore, some questions you may consider asking yourself are:
am I looking after my appearance to the best of my ability?
Are my clothes appropriate for the image I wish to project?
3. Be Positive and Enthusiastic
Positivity and enthusiasm can both be developed, but once again it takes work. Here are a few tips to help you:
* Look for the best in people
* Associate with positive people
* Care deeply about something
* See life as an adventure
* Smile
4. Be Real and Authentic
Selling yourself is about letting others know who you are as a person.
The product? You !
When you think about it, if you cannot sell yourself as a person to others, you are going to have a difficult time selling them your ideas, your wishes, your needs, your ambitions, your skills, and your experience.
Despite the necessity of being able to sell yourself to others, for many people like myself it does not come naturally. Introversion, shyness, and lack of self-worth are just a few of the obstacles that can potentially get in the way. To overcome such obstacles, I suggest focusing on the following:
1. Be Sold on Yourself
This is probably also the hardest. Being sold on yourself comes down to this: you must be aware of your own self-worth. This means you believe in yourself, have faith in yourself, and have confidence in yourself.
Here are just 3 ideas that may help:
* Live in such a way that you would want to be friends with yourself
* Find some time to reflect on what you like about yourself. If this seems hard, start with the smallest of attributes.
* Don’t do anything that will give you cause to feel ashamed later.
2. Have a Saleable Package
Let others know about the inner contents of your package.
People judge others based on their appearance.
Therefore, some questions you may consider asking yourself are:
am I looking after my appearance to the best of my ability?
Are my clothes appropriate for the image I wish to project?
3. Be Positive and Enthusiastic
Positivity and enthusiasm can both be developed, but once again it takes work. Here are a few tips to help you:
* Look for the best in people
* Associate with positive people
* Care deeply about something
* See life as an adventure
* Smile
4. Be Real and Authentic
Selling yourself is about letting others know who you are as a person.
Wednesday, February 3, 2010
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephriti
Original Article
Kidney International (2010) 77, 152–160; doi:10.1038/ki.2009.412; published online 4 November 2009
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Jai Radhakrishnan1,6, Dimitrios-Anestis Moutzouris2,6, Ellen M Ginzler3, Neil Solomons4, Ilias I Siempos5 and Gerald B Appel1
Class V lupus nephritis (LN) occurs in one-fifth of biopsy-proven cases of systemic lupus erythematosus. To study the effectiveness of treatments in this group of patients, we pooled analysis of two large randomized controlled multicenter trials of patients with diverse ethnic and racial background who had pure class V disease. These patients received mycophenolate mofetil (MMF) or intravenous cyclophosphamide (IVC) as induction therapy for 24 weeks, with percentage change in proteinuria and serum creatinine as end points. Weighted mean differences, pooled odds ratios, and confidence intervals were calculated by using a random-effects model. A total of 84 patients with class V disease were divided into equal groups, each group had comparable entry variables but one received MMF and one received IVC. Within these groups, 33 patients on MMF and 32 patients on IVC completed 24 weeks of treatment. There were no differences between the groups in mean values for the measured end points. Similarly, no difference was found regarding the number of patients who did not complete the study or who died. In patients with nephrotic syndrome, no difference was noted between those treated with MMF and IVC regarding partial remission or change in urine protein. Hence we found that the response to MMF as induction treatment of patients with class V LN appears to be no different from that to IVC.
Kidney International (2010) 77, 152–160; doi:10.1038/ki.2009.412; published online 4 November 2009
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis
Jai Radhakrishnan1,6, Dimitrios-Anestis Moutzouris2,6, Ellen M Ginzler3, Neil Solomons4, Ilias I Siempos5 and Gerald B Appel1
Class V lupus nephritis (LN) occurs in one-fifth of biopsy-proven cases of systemic lupus erythematosus. To study the effectiveness of treatments in this group of patients, we pooled analysis of two large randomized controlled multicenter trials of patients with diverse ethnic and racial background who had pure class V disease. These patients received mycophenolate mofetil (MMF) or intravenous cyclophosphamide (IVC) as induction therapy for 24 weeks, with percentage change in proteinuria and serum creatinine as end points. Weighted mean differences, pooled odds ratios, and confidence intervals were calculated by using a random-effects model. A total of 84 patients with class V disease were divided into equal groups, each group had comparable entry variables but one received MMF and one received IVC. Within these groups, 33 patients on MMF and 32 patients on IVC completed 24 weeks of treatment. There were no differences between the groups in mean values for the measured end points. Similarly, no difference was found regarding the number of patients who did not complete the study or who died. In patients with nephrotic syndrome, no difference was noted between those treated with MMF and IVC regarding partial remission or change in urine protein. Hence we found that the response to MMF as induction treatment of patients with class V LN appears to be no different from that to IVC.
Sunday, January 31, 2010
Friday, January 29, 2010
Thursday, January 21, 2010
Experts: Sitting too much could be deadly
LONDON – Here's a new warning from health experts: Sitting is deadly.
Scientists are increasingly warning that sitting for prolonged periods — even if you also exercise regularly — could be bad for your health. And it doesn't matter where the sitting takes place — at the office, at school, in the car or before a computer or TV — just the overall number of hours it occurs.
Research is preliminary, but several studies suggest people who spend most of their days sitting are more likely to be fat, have a heart attack or even die.
In an editorial published this week in the British Journal of Sports Medicine, Elin Ekblom-Bak of the Swedish School of Sport and Health Sciences suggested that authorities rethink how they define physical activity to highlight the dangers of sitting.
While health officials have issued guidelines recommending minimum amounts of physical activity, they haven't suggested people try to limit how much time they spend in a seated position.
"After four hours of sitting, the body starts to send harmful signals," Ekblom-Bak said. She explained that genes regulating the amount of glucose and fat in the body start to shut down.
Even for people who exercise, spending long stretches of time sitting at a desk is still harmful. Tim Armstrong, a physical activity expert at the World Health Organization, said people who exercise every day — but still spend a lot of time sitting — might get more benefit if that exercise were spread across the day, rather than in a single bout.
That wasn't welcome news for Aytekin Can, 31, who works at a London financial company, and spends most of his days sitting in front of a computer. Several evenings a week, Can also teaches jiu jitsu, a Japanese martial art involving wrestling, and also does Thai boxing.
"I'm sure there are some detrimental effects of staying still for too long, but I hope that being active when I can helps," he said. "I wouldn't want to think the sitting could be that dangerous."
Still, in a study published last year that tracked more than 17,000 Canadians for about a dozen years, researchers found people who sat more had a higher death risk, independently of whether or not they exercised.
"We don't have enough evidence yet to say how much sitting is bad," said Peter Katzmarzyk of the Pennington Biomedical Research Center in Baton Rouge, who led the Canadian study. "But it seems the more you can get up and interrupt this sedentary behavior, the better."
Figures from a U.S. survey in 2003-2004 found Americans spend more than half their time sitting, from working at their desks to sitting in cars.
Experts said more research is needed to figure out just how much sitting is dangerous, and what might be possible to offset those effects.
"People should keep exercising because that has a lot of benefits," Ekblom-Bak said. "But when they're in the office, they should try to interrupt sitting as often as possible," she said. "Don't just send your colleague an e-mail. Walk over and talk to him. Standing up."
Scientists are increasingly warning that sitting for prolonged periods — even if you also exercise regularly — could be bad for your health. And it doesn't matter where the sitting takes place — at the office, at school, in the car or before a computer or TV — just the overall number of hours it occurs.
Research is preliminary, but several studies suggest people who spend most of their days sitting are more likely to be fat, have a heart attack or even die.
In an editorial published this week in the British Journal of Sports Medicine, Elin Ekblom-Bak of the Swedish School of Sport and Health Sciences suggested that authorities rethink how they define physical activity to highlight the dangers of sitting.
While health officials have issued guidelines recommending minimum amounts of physical activity, they haven't suggested people try to limit how much time they spend in a seated position.
"After four hours of sitting, the body starts to send harmful signals," Ekblom-Bak said. She explained that genes regulating the amount of glucose and fat in the body start to shut down.
Even for people who exercise, spending long stretches of time sitting at a desk is still harmful. Tim Armstrong, a physical activity expert at the World Health Organization, said people who exercise every day — but still spend a lot of time sitting — might get more benefit if that exercise were spread across the day, rather than in a single bout.
That wasn't welcome news for Aytekin Can, 31, who works at a London financial company, and spends most of his days sitting in front of a computer. Several evenings a week, Can also teaches jiu jitsu, a Japanese martial art involving wrestling, and also does Thai boxing.
"I'm sure there are some detrimental effects of staying still for too long, but I hope that being active when I can helps," he said. "I wouldn't want to think the sitting could be that dangerous."
Still, in a study published last year that tracked more than 17,000 Canadians for about a dozen years, researchers found people who sat more had a higher death risk, independently of whether or not they exercised.
"We don't have enough evidence yet to say how much sitting is bad," said Peter Katzmarzyk of the Pennington Biomedical Research Center in Baton Rouge, who led the Canadian study. "But it seems the more you can get up and interrupt this sedentary behavior, the better."
Figures from a U.S. survey in 2003-2004 found Americans spend more than half their time sitting, from working at their desks to sitting in cars.
Experts said more research is needed to figure out just how much sitting is dangerous, and what might be possible to offset those effects.
"People should keep exercising because that has a lot of benefits," Ekblom-Bak said. "But when they're in the office, they should try to interrupt sitting as often as possible," she said. "Don't just send your colleague an e-mail. Walk over and talk to him. Standing up."
Friday, January 15, 2010
Tuesday, January 12, 2010
Monday, January 11, 2010
Renal and cardio-protective effects of direct renin inhibition: a systematic literature review
Journal of Hypertension
Issue: Volume 27(12), December 2009, p 2321–2331
Copyright: © 2009 Lippincott Williams & Wilkins, Inc.
Publication Type: [Meta-analyses]
aDepartment of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
bGeorge Institute for International Health, University of Sydney, Sydney, Australia
Results: Fifty-two articles were included. Blood pressure reductions were generally insufficient using early generation DRIs. However, recent DRIs have greater blood pressure-lowering effects. Preclinical and clinical studies showed profound effects of DRIs on markers of renal function, including clear increases in renal plasma flow and reductions in albuminuria. These effects were observed either alone or in combination with other RAAS inhibitors and suggest potential large renal protective benefit. DRIs improved hemodynamic cardiovascular parameters, such as total peripheral resistance, arterial pressure and left ventricular mass index, to a similar extent as those observed with other RAAS inhibitors. Furthermore, addition of DRIs to optimal heart failure treatment resulted in further reductions in B-type natriuretic peptide.
Conclusions: Evidence from preclinical and clinical studies suggests that DRIs may have renal and cardiovascular effects beyond their ability to lower blood pressure. Results of ongoing hard outcome trials are awaited to definitively assess the renal and cardio-protective effects of these agents.
Issue: Volume 27(12), December 2009, p 2321–2331
Copyright: © 2009 Lippincott Williams & Wilkins, Inc.
Publication Type: [Meta-analyses]
aDepartment of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
bGeorge Institute for International Health, University of Sydney, Sydney, Australia
Results: Fifty-two articles were included. Blood pressure reductions were generally insufficient using early generation DRIs. However, recent DRIs have greater blood pressure-lowering effects. Preclinical and clinical studies showed profound effects of DRIs on markers of renal function, including clear increases in renal plasma flow and reductions in albuminuria. These effects were observed either alone or in combination with other RAAS inhibitors and suggest potential large renal protective benefit. DRIs improved hemodynamic cardiovascular parameters, such as total peripheral resistance, arterial pressure and left ventricular mass index, to a similar extent as those observed with other RAAS inhibitors. Furthermore, addition of DRIs to optimal heart failure treatment resulted in further reductions in B-type natriuretic peptide.
Conclusions: Evidence from preclinical and clinical studies suggests that DRIs may have renal and cardiovascular effects beyond their ability to lower blood pressure. Results of ongoing hard outcome trials are awaited to definitively assess the renal and cardio-protective effects of these agents.
Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. Chan, Clara, Reid, Christopher, Aw, Tai-
Journal of Hypertension
Volume 27(12) December 2009
(C) 2009 Lippincott Williams & Wilkins, Inc.
Conclusion: On the basis of this updated meta-analysis, coxibs appear to produce greater hypertension than either ns-NSAIDs or placebo. However, this response was heterogeneous, with markedly raised BP associated with rofecoxib and etoricoxib, whereas celecoxib, valdecoxib and lumiracoxib appeared to have little BP effect. The relationship of this increased risk of hypertension to subsequent adverse CV outcomes requires further investigation and prospective RCTs.
Volume 27(12) December 2009
(C) 2009 Lippincott Williams & Wilkins, Inc.
Conclusion: On the basis of this updated meta-analysis, coxibs appear to produce greater hypertension than either ns-NSAIDs or placebo. However, this response was heterogeneous, with markedly raised BP associated with rofecoxib and etoricoxib, whereas celecoxib, valdecoxib and lumiracoxib appeared to have little BP effect. The relationship of this increased risk of hypertension to subsequent adverse CV outcomes requires further investigation and prospective RCTs.
Subscribe to:
Posts (Atom)
Posts
